$1.81 -0.13 (-6.57%)
Climb Bio, Inc. Common Stock (CLYM)
Climb Bio, Inc. (CLYM) is a biotechnology company focused on developing innovative therapies targeting neurodegenerative diseases. The company leverages its proprietary platforms to discover and advance drug candidates aimed at addressing unmet medical needs in neurosciences.
Company News
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
Climb Bio, a clinical-stage biotechnology company, will participate in multiple healthcare investor conferences in September 2025, presenting its pipeline of therapeutics for immune-mediated diseases.